)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Turn Therapeutics
Turn Therapeutics (TTRX) investor relations material
Turn Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary31 Mar, 2026
Executive summary
Achieved significant progress in clinical, financial, and strategic priorities during first months as a public company.
Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis remains on track, with topline results expected mid-2026.
Entered global license, supply, and distribution agreement with Medline, enabling potential revenue generation in late 2026.
Expanded intranasal vaccine pipeline to include a thermostable influenza candidate.
Financial highlights
Cash and cash equivalents as of December 31, 2025, were $5.08 million, excluding $7.0 million from Avenue Capital facility.
Research and development expenses for 2025 were $0.3 million, up from $0.2 million in 2024.
General and administrative expenses rose to $5.5 million in 2025 from $1.5 million in 2024, mainly due to costs associated with public listing.
Net loss for 2025 was $3.19 million, compared to $1.77 million in 2024.
Basic and diluted net loss per share was $0.12 in 2025, compared to $0.07 in 2024.
Outlook and guidance
Growth capital from Avenue Capital extends cash runway through end of 2027, supporting continued investment in therapeutic programs.
Topline results for GX-03 Phase 2 trial expected mid-2026; commercial revenue anticipated to begin in late 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Turn Therapeutics
- Phase II eczema trial for a novel IL-36/IL-31 inhibitor expects key data in Q2 2026.TTRX
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - GX-03 targets key cytokines in eczema and onychomycosis with strong safety and efficacy data.TTRXCorporate presentation2 Mar 2026
- Lead topical for eczema in phase II, with phase III trials planned and strong safety data.TTRXOppenheimer 36th Annual Healthcare Life Sciences Conference25 Feb 2026
- Strong clinical data, FDA clearances, and strategic partnerships drive growth and market expansion.TTRXOpen Investor Session materials presentation20 Jan 2026
- GX-03 targets IL-36-driven inflammation, showing strong efficacy in eczema and nail fungus.TTRXCorporate presentation20 Jan 2026
- Direct listing for a clinical-stage drug/device firm with founder control, no revenue, and high capital needs.TTRXRegistration Filing20 Jan 2026
- Net loss increased to $1.90M; Nasdaq listing and partnerships support future operations.TTRXQ3 202520 Jan 2026
- Direct listing on Nasdaq offers up to 17.8M shares for resale; no proceeds to the company.TTRXRegistration Filing20 Jan 2026
- Proprietary drug/device developer relies on GEM equity facility for funding amid ongoing losses.TTRXRegistration Filing20 Jan 2026
Next Turn Therapeutics earnings date
Q1 202614 May, 2026
Turn Therapeutics
Next Turn Therapeutics earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage